Stocks in Focus: (NASDAQ: ZIOP), (NASDAQ: OCZ)
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced the initiation of a randomized, open label Phase 2 clinical study of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.
View full press release